Related Experiment Videos

From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design

Ana Ramírez de Molina1, Agustín Rodríguez-González, Juan Carlos Lacal

  • 1Department of Molecular and Cellular Biology of Cancer, Instituto de Investigaciones Biomédicas, CSIC, Arturo Duperier 4, Madrid 28029, Spain.

Cancer Letters
|March 12, 2004
PubMed

Insights

Cancer cells exhibit uncontrolled proliferation due to activated signaling pathways. Targeting Ras GTPases offers a promising model for developing novel, patient-specific cancer therapies to improve survival rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer is a prevalent genetic disease with high mortality, characterized by uncontrolled cell proliferation.
  • Activated signal transduction pathways drive tumorigenesis, necessitating targeted molecular interventions.
  • Despite advances, novel, personalized therapies are crucial for improving cancer patient survival.

Purpose of the Study:

  • To review the role of Ras GTPases in human carcinogenesis.
  • To explore Ras-dependent signaling as a model for developing targeted cancer therapies.
  • To highlight the potential of Ras GTPase-focused strategies for personalized oncology.

Main Methods:

  • Literature review of cancer genetics and signaling pathways.
  • Analysis of Ras GTPase function in normal and oncogenic contexts.
  • Discussion of therapeutic strategies targeting Ras signaling.

Main Results:

  • Ras GTPases are key oncogenes implicated in human carcinogenesis.
  • Understanding Ras signaling regulation provides insights into tumor development.
  • Ras pathways are critical targets for novel antitumor drug design.

Conclusions:

  • The Ras GTPase family serves as a valuable model for developing innovative cancer treatments.
  • Targeting Ras-dependent signaling can lead to more effective and personalized cancer therapies.
  • Further research into Ras GTPases holds significant promise for improving cancer patient outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...